# MariTide phase 3 results (MARITIME-1): what to expect

Source: https://pepvault.app/guides/maritime-1-results

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# MariTide phase 3 results (MARITIME-1): what to expect

Reviewed November 2026 14 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

MariTide's phase 3 MARITIME-1 trial: what it tests, what phase 2 showed, the bar Zepbound and Wegovy set, and when the 72-week results are expected.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 14
- **Questions:** 6
- **Compounds:** 3

## The short answer

MARITIME-1 has not reported as of November 20, 2026. The 72-week phase 3 trial tests three doses of Amgen's MariTide, a once-a-month shot, against placebo in 3,853 adults with obesity and no diabetes. The registry estimates primary completion for January 21, 2027. The bars to clear at 72 weeks: tirzepatide's 20.9% and high-dose Wegovy's 18.8%, with fewer people stopping for side effects than the 11% in phase 2's step-up arms.

Every number checked at its primary source · Nov 20, 2026 · [14 sources](https://pepvault.app/guides/maritime-1-results#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** One randomised phase 2 trial in 592 people (NEJM 2025) and a phase 1 trial in people, with the phase 3 design from ClinicalTrials.gov and Amgen's releases; MARITIME-1 and MARITIME-2 have not reported, and MariTide is investigational.

## What is MARITIME-1 testing?

MARITIME-1 is MariTide's lead phase 3 weight-loss trial, and its result will show whether one injection every four weeks can keep up with the weekly drugs. Amgen enrolled 3,853 adults, randomly assigned to a high, medium or low dose of maridebart cafraglutide (MariTide) or to placebo, a dummy shot, for 72 weeks. It is double-blind: neither the participants nor the investigators know who gets what[1](https://pepvault.app/guides/maritime-1-results#source-1).

| Design | MARITIME-1 | MARITIME-2 |
| --- | --- | --- |
| Registry number | NCT06858839 | NCT06858878 |
| Who | Adults with a BMI of 30 or more, or 27 to 30 with a weight-related condition such as high blood pressure or sleep apnea; no diabetes | Adults with type 2 diabetes and a BMI of 27 or more |
| People enrolled | 3,853 | 1,105 |
| Arms | MariTide high, medium or low dose, or placebo | MariTide high, medium or low dose, or placebo |
| Length | 72 weeks | 72 weeks |
| Primary endpoint | Percent change in body weight at week 72 | Percent change in body weight at week 72 |
| Primary completion (registry estimate) | January 21, 2027 | January 21, 2027 |

Both rows come from the ClinicalTrials.gov records, read on November 20, 2026[1](https://pepvault.app/guides/maritime-1-results#source-1) [2](https://pepvault.app/guides/maritime-1-results#source-2). The primary endpoint is the one result a trial is built to answer. MARITIME-2 also measures blood sugar (HbA1c, the three-month average), but as a secondary endpoint[2](https://pepvault.app/guides/maritime-1-results#source-2).

Every MariTide arm opens the same way. Amgen states that participants start at 21 mg, step to 35 mg and then 70 mg over eight weeks, and then move to their assigned target dose[5](https://pepvault.app/guides/maritime-1-results#source-5). The registry does not name the three target amounts[1](https://pepvault.app/guides/maritime-1-results#source-1), and neither has Amgen. They are trial doses, not a regimen.

The drug itself is built unusually: a full antibody that blocks the GIP receptor, carrying two GLP-1 peptides that switch the GLP-1 receptor on[3](https://pepvault.app/guides/maritime-1-results#source-3). The antibody is what lets it last: in phase 1 its half-life was about 14 to 16 days for the active form and 21 to 24 days for the antibody overall[9](https://pepvault.app/guides/maritime-1-results#source-9). PepVault's guide to monthly GLP-1 shots covers how it works in full.

Try it

How MariTide builds up

An estimate from a half-life of about 15 days, one dose a week for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [MariTide in the library](https://pepvault.app/peptides/maritide)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault charts every weigh-in from your starting weight, so you can set your own change next to these trial averages.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What did MariTide's phase 2 trial show?

Phase 2, published in the New England Journal of Medicine in 2025, gave 592 people MariTide or placebo for 52 weeks[3](https://pepvault.app/guides/maritime-1-results#source-3). In the 465 people without diabetes, average weight loss counting everyone, including those who stopped the drug, ran from 12.3% to 16.2% across the doses, against 2.5% on placebo[3](https://pepvault.app/guides/maritime-1-results#source-3). Counting only those who kept taking it, the range was 16.3% to 19.9%, against 2.6%[5](https://pepvault.app/guides/maritime-1-results#source-5).

Two details matter for phase 3. First, Amgen reported no weight-loss plateau by week 52[4](https://pepvault.app/guides/maritime-1-results#source-4), so a 72-week trial gives the curve 20 more weeks to fall. Second, in the 127 people with type 2 diabetes, weight fell 8.4% to 12.3% and HbA1c fell 1.2 to 1.6 points, against 1.7% and a 0.1-point rise on placebo[3](https://pepvault.app/guides/maritime-1-results#source-3). That is the group MARITIME-2 now tests at full size.

Phase 2 tested 140, 280 and 420 mg every four weeks, 420 mg every eight weeks, and two arms that climbed to 420 mg over four or twelve weeks[3](https://pepvault.app/guides/maritime-1-results#source-3). In a second year, people who had lost at least 15% moved to a lower monthly dose or a quarterly shot, and Amgen reported that the large majority kept their loss for another 52 weeks[11](https://pepvault.app/guides/maritime-1-results#source-11); it has not given the numbers. Phase 3 tests the same idea next: the MARITIME-1 extension, now enrolling, moves people who finish the trial to monthly, every-eight-week or quarterly dosing[10](https://pepvault.app/guides/maritime-1-results#source-10).

## How does MariTide compare with Zepbound and Wegovy so far?

The fair comparison is the measure that counts everyone, including people who stopped, because that is the figure each of these trials led with. On that measure, MariTide's best phase 2 arm, 16.2%, sits above Wegovy's 2.4 mg dose and below tirzepatide 15 mg and Wegovy's newer 7.2 mg dose, after a shorter trial[3](https://pepvault.app/guides/maritime-1-results#source-3) [6](https://pepvault.app/guides/maritime-1-results#source-6) [7](https://pepvault.app/guides/maritime-1-results#source-7) [8](https://pepvault.app/guides/maritime-1-results#source-8).

| Trial | Drug and dose | Length | Average weight loss, everyone counted | Placebo | Stopped for side effects |
| --- | --- | --- | --- | --- | --- |
| MariTide phase 2[3](https://pepvault.app/guides/maritime-1-results#source-3) [4](https://pepvault.app/guides/maritime-1-results#source-4) [5](https://pepvault.app/guides/maritime-1-results#source-5) | 140 to 420 mg, every 4 or 8 weeks | 52 weeks | 12.3% to 16.2% | 2.5% | About 11% in the step-up arms; up to 7.8% for stomach side effects, more in arms with no step-up |
| SURMOUNT-1[6](https://pepvault.app/guides/maritime-1-results#source-6) | Tirzepatide 15 mg weekly (Zepbound) | 72 weeks | 20.9% | 3.1% | 6.2%, against 2.6% on placebo |
| SURMOUNT-1[6](https://pepvault.app/guides/maritime-1-results#source-6) | Tirzepatide 5 mg weekly | 72 weeks | 15.0% | 3.1% | 4.3% |
| STEP 1[7](https://pepvault.app/guides/maritime-1-results#source-7) [8](https://pepvault.app/guides/maritime-1-results#source-8) | Semaglutide 2.4 mg weekly (Wegovy) | 68 weeks | 14.9% | 2.4% | 4.5% for stomach side effects, against 0.8%; 6.8% for any, against 3.2%, across the label's trials |
| STEP UP, Wegovy label Study 8[8](https://pepvault.app/guides/maritime-1-results#source-8) | Semaglutide 7.2 mg weekly (Wegovy) | 72 weeks | 18.8% | 3.9% | 5.4%, against 1% on placebo |

Lengths differ: phase 2 stopped at 52 weeks, and MARITIME-1 runs 72, the same as SURMOUNT-1 and STEP UP. Semaglutide 2.4 mg's 6.8% comes from the Wegovy label's pooled weight trials, not STEP 1 alone[8](https://pepvault.app/guides/maritime-1-results#source-8).

<!--promo-->

PepVault charts every weigh-in from your starting weight, so you can set your own change next to these trial averages. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-maritime-1-results-inline&mt=8)

<!--/promo-->

## With this guide

### MariTide

- [MariTide: the full reference](https://pepvault.app/peptides/maritide)
- [MariTide dose guide](https://pepvault.app/lab/dosage/maritide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

## What would count as a good MARITIME-1 result?

Amgen has set no public target, so here is PepVault's reading, written before the result so it cannot bend to fit it. The comparator trials set the bars, and MARITIME-1 reports the same week-72 measures[1](https://pepvault.app/guides/maritime-1-results#source-1) [6](https://pepvault.app/guides/maritime-1-results#source-6).

- **Weight, top dose, everyone counted:** about 21% or more matches tirzepatide 15 mg at the same week[6](https://pepvault.app/guides/maritime-1-results#source-6). About 19% to 20% beats high-dose Wegovy's 18.8% at week 72[8](https://pepvault.app/guides/maritime-1-results#source-8). Between 15% and 19% sits with Wegovy 2.4 mg (14.9% at week 68[7](https://pepvault.app/guides/maritime-1-results#source-7)), with monthly dosing as its edge. Under 15% falls short of the weekly shots.
- **Share losing 20% or more:** a secondary endpoint of MARITIME-1[1](https://pepvault.app/guides/maritime-1-results#source-1). On tirzepatide 15 mg it was 57%, against 3% on placebo[6](https://pepvault.app/guides/maritime-1-results#source-6).
- **Stopping for side effects:** about 7% or less would put MariTide level with the weekly drugs (6.2% on tirzepatide 15 mg; 6.8% on Wegovy 2.4 mg and 5.4% on 7.2 mg)[6](https://pepvault.app/guides/maritime-1-results#source-6) [8](https://pepvault.app/guides/maritime-1-results#source-8). That is the number to watch, because phase 2's step-up arms lost about 11% to side effects[4](https://pepvault.app/guides/maritime-1-results#source-4).
- **The first weeks:** how many people vomit after the opening doses, the figure the lower 21 mg start was built to bring down[5](https://pepvault.app/guides/maritime-1-results#source-5).

Tolerability was phase 2's talking point. Nausea and vomiting came mainly with the first dose and were much less common when the dose was stepped up[4](https://pepvault.app/guides/maritime-1-results#source-4). Amgen then ran a phase 1 study of lower starts: with 21 mg, then 70 mg, then 350 mg, 24.4% vomited at some point and no one stopped for stomach side effects[5](https://pepvault.app/guides/maritime-1-results#source-5). Phase 3's 21, 35, 70 mg climb came out of that work[5](https://pepvault.app/guides/maritime-1-results#source-5).

**Commonly reported:** in the phase 2 step-up arms, nausea that came in episodes and settled within a median of about six days, and vomiting that lasted one to two days, mostly after the first dose[4](https://pepvault.app/guides/maritime-1-results#source-4).

## When will MARITIME-1 results come out?

The registry's primary completion date, January 21, 2027, is an estimate of when the last participant reaches the week-72 weigh-in, not a results date; the full study runs to an estimated April 16, 2027[1](https://pepvault.app/guides/maritime-1-results#source-1) [2](https://pepvault.app/guides/maritime-1-results#source-2). Amgen has not stated when it will report: its November 3, 2026 quarterly release lists both trials as ongoing with no readout date[10](https://pepvault.app/guides/maritime-1-results#source-10).

Phase 2 shows the usual pace. Its primary completion was October 8, 2024[12](https://pepvault.app/guides/maritime-1-results#source-12), Amgen's topline release followed on November 26, 2024[4](https://pepvault.app/guides/maritime-1-results#source-4), and the full results came at the American Diabetes Association meeting and in the journal on June 23, 2025[5](https://pepvault.app/guides/maritime-1-results#source-5) [3](https://pepvault.app/guides/maritime-1-results#source-3). The same gaps would put a MARITIME-1 topline in early 2027, as an expectation, not a promise.

| Date | What could happen |
| --- | --- |
| January 21, 2027 | Primary completion, the registry's estimate for both trials[1](https://pepvault.app/guides/maritime-1-results#source-1) [2](https://pepvault.app/guides/maritime-1-results#source-2) |
| Early 2027 | An Amgen topline press release, if phase 2's pace holds (PepVault's expectation) |
| May 18 to 21, 2027 | European Congress on Obesity, Munich[14](https://pepvault.app/guides/maritime-1-results#source-14) |
| June 18 to 21, 2027 | American Diabetes Association Scientific Sessions, Washington, D.C.[13](https://pepvault.app/guides/maritime-1-results#source-13) |

The ADA's regular abstract deadline, January 5, 2027, falls before the registry's primary completion date[13](https://pepvault.app/guides/maritime-1-results#source-13); a full presentation that June would depend on the meeting's late-breaking slots or a journal paper.

<!--promo-->

PepVault can schedule a shot every four weeks today, as a cycle of one day on and 27 days off: the reminder comes on the day it is due, and the log keeps every shot with its date. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-maritime-1-results-inline&mt=8)

<!--/promo-->

## Has MARITIME-1 reported yet?

**Not reported as of November 20, 2026.** When Amgen releases the topline, this section will carry, for each of the three doses and placebo: the average weight change at week 72 counting everyone and counting only those who stayed on the drug, the share reaching 10%, 15% and 20%, the rate of stopping for side effects, and the target doses, which are still unnamed. MARITIME-2's numbers, including HbA1c, will sit beside them[2](https://pepvault.app/guides/maritime-1-results#source-2).

MariTide is investigational and approved nowhere. For the drug itself, PepVault's MariTide page in the library covers its mechanism, half-life and trial timeline. The Zepbound and Wegovy bars above each have their own study page in PepVault's research section: SURMOUNT-1, STEP 1 and STEP UP.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. ClinicalTrials.gov NCT06858839. MARITIME-1: maridebart cafraglutide in adults without type 2 diabetes who have obesity or are overweight (phase 3; sponsor Amgen). Record updated September 17, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858839)
2. ClinicalTrials.gov NCT06858878. MARITIME-2: maridebart cafraglutide in adults with type 2 diabetes who have obesity or are overweight (phase 3; sponsor Amgen). Record updated December 31, 2025. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858878)
3. Jastreboff AM et al. Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial. N Engl J Med. 2025;393(9):843-857. [PubMed 40549887](https://pubmed.ncbi.nlm.nih.gov/40549887/)
4. Amgen. Amgen announces robust weight loss with MariTide in people living with obesity or overweight at 52 weeks in a phase 2 study. Press release, November 26, 2024. [amgen.com](https://www.amgen.com/newsroom/press-releases/2024/11/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52-weeks-in-a-phase-2-study)
5. Amgen. Results from Amgen's phase 2 obesity study of monthly MariTide presented at the American Diabetes Association 85th Scientific Sessions. Press release, June 23, 2025. [amgen.com](https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions)
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. [PubMed 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. [PubMed 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
8. Wegovy (semaglutide) prescribing information, sections 6.1 and 14.2 (Studies 8 and 9, the 7.2 mg dose). Novo Nordisk. DailyMed, version 19, June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
9. Véniant MM et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290-303. [PubMed 38316982](https://pubmed.ncbi.nlm.nih.gov/38316982/)
10. Amgen. Amgen reports third quarter 2026 financial results. Press release, November 3, 2026. [amgen.com](https://www.amgen.com/newsroom/press-releases/2026/11/amgen-reports-third-quarter-2026-financial-results)
11. Amgen. Amgen reports fourth quarter and full year 2025 financial results. Press release, February 3, 2026. [amgen.com](https://www.amgen.com/newsroom/press-releases/2026/02/amgen-reports-fourth-quarter-and-full-year-2025-financial-results)
12. ClinicalTrials.gov NCT05669599. Phase 2 study of AMG 133 (maridebart cafraglutide) in adults with obesity, with or without type 2 diabetes (sponsor Amgen). Primary completion October 8, 2024. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05669599)
13. American Diabetes Association. Scientific Sessions: save the date, Washington, D.C., June 18-21, 2027. [professional.diabetes.org](https://professional.diabetes.org/scientific-sessions)
14. ECO2027: the 34th European Congress on Obesity, Munich, 18-21 May 2027 (congress site). [eco2027.org](https://eco2027.org/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)

Aleniglipron is Structure Therapeutics' daily GLP-1 pill in testing: its phase 2 numbers, every trial, and what its shot-to-pill SWITCH trial must beat.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [MariTide Studied range: 21–420 mg](https://pepvault.app/peptides/maritide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)

  No monthly GLP-1 shot is approved yet. MariTide and berobenatide are in phase 3: how one shot lasts a month, what phase 2 found, and when results are due.

  Read the guide
- Guide · GLP-1s

  ### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

  What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### MariTide

- [MariTide: the full reference](https://pepvault.app/peptides/maritide)
- [MariTide dose guide](https://pepvault.app/lab/dosage/maritide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
